为探究乳腺癌脑转移（BCBMs）治疗策略变化对患者结局的影响，意大利和法国多家机构研究人员开展相关研究。结果发现仅 HR-/HER2 + 患者总生存期改善。该研究对优化治疗、评估预后意义重大，值得科研读者一读。

美国食品药品监督管理局（FDA）已对zongertinib的新药申请给予优先审查，用于治疗肿瘤具有人类表皮生长因子受体2（HER2/ERBB2）突变且已接受过全身治疗的不可切除或转移性非小细胞肺癌（NSCLC）成年患者。

此外，在2024年世界肺癌大会上发表的数据还显示，zongertinib具有初步的脑活性。根据盲法独立中央审评（BICR）的评估，33%（120 mg，n=27）和40%（240 ...

Dr. Debu Tripathy breaks down the FDA approval of Enhertu in unresectable or metastatic HR-positive, HER2-low or -ultralow ...

2025 年 1 月 18 日，由北京市希思科临床肿瘤学研究基金会、杭州东方临床肿瘤研究中心共同主办的「2024 胃肠肿瘤年终大盘点」盛大召开。会议中揭榜 2024 胃肠领域十大临床热词，其中，肿瘤经典靶点人表皮生长因子受体 2（HER2）和抗 ...

HER2-positive (HER2+) breast cancer treatments come with a range of unpleasant side effects. However, there are strategies ...

Ridgefield, Conn., U.S., and Ingelheim, GermanyZongertinib would be the first orally administered, targeted therapy for previously treated ...

A new study on circulating tumor DNA (ctDNA) testing for advanced breast cancer has unveiled encouraging results, with high ...

San Antonio Breast Cancer Symposium 2024 provided multiple updates in the field of HER2-positive breast cancer, including novel treatments, new treatment regimens and more.See Healio’s highlights in H ...

Dr. Debu Tripathy discussed the importance of understanding the distinctions between HER2-low and HER2-ultralow breast cancer.

The treatment landscape for HER2-positive NSCLC is rapidly evolving as research continues to reveal the genetic drivers of these tumors. Emerging therapies like Pyrotinib (Jiangsu HengRui Medicine), ...

No improvement in overall survival (OS) was observed with palbociclib (Verzenio) plus endocrine therapy versus capecitabine ...